TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

Fate Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 22, 2023 to Discuss Your Rights - FATE

Newsfile 25-Jan-2023 5:34 PM

New York, New York--(Newsfile Corp. - January 25, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ:FATE) of a class action securities lawsuit.

The lawsuit on behalf of Fate investors has been commenced in the the United States District Court for the Southern District of California. Affected investors purchased or otherwise acquired certain Fate Therapeutics, Inc. securities between April 2, 2020 and January 5, 2023. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=35944&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/152528_973567_logo.jpg

Fate Therapeutics, Inc. NEWS - FATE NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the global collaboration and option agreement for cell-based cancer immunotherapies that the Company entered into with Janssen Biotech, Inc. (the "Janssen Collaboration Agreement") was less sustainable than Fate had represented to investors; (ii) accordingly, certain the clinical programs, milestone payments, and royalty payments associated with the Janssen Collaboration Agreement could not be relied upon as future revenue sources; (iii) as a result, Fate had overstated the impact of the Janssen Collaboration Agreement's on Fate's long-term clinical and commercial profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Fate during the relevant timeframe, you have until March 22, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/fate-therapeutics-class-action-submission-form?prid=35944&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/152528

Image for Press Release 1627423